spacer
home > pmps > winter 2001 > preventive medicine - why the pharmaceutical industry needs to invest in prevention and cure to ensure effective brande protection
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Preventive Medicine - Why the Pharmaceutical Industry Needs to Invest in Prevention and Cure to Ensure Effective Brande Protection

Historically, pharmaceutical companies have tended to adopt a pragmatically conservative approach to problems of brand infringement and counterfeiting. Whilst they are ready to act whenever threats to public safety arise, they are understandably reluctant to publicise such incidents for fear of adverse effects on consumer confidence and share prices. However, a reactive approach to brand protection is becoming increasingly untenable - the changing value and role of pharmaceutical brands and the globalisation of the market present issues that demand a more comprehensive protection strategy.

New Market Trends - New Risks

A number of emerging trends in the pharmaceutical industry have serious implications for manufacturers and the ways in which they protect themselves, their products and, ultimately, their profits.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keith Widdowson of De La Rue Brand Protection - Pharmaceuticals
Keith Widdowson has worked in the pharmaceutical industry for nearly 20 years, in some of the largest pharma companies such as AstraZeneca and Novartis. He has recently been responsible for ensuring that major brands are truly global and he has applied key branding elements to all commercial and manufacturing components.

spacer
Keith Widdowson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement